» Articles » PMID: 8652023

Skeletal, Cardiac, and Smooth Muscle Failure in Duchenne Muscular Dystrophy

Overview
Journal Pediatr Neurol
Specialties Neurology
Pediatrics
Date 1996 Jan 1
PMID 8652023
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The goals of this study were to describe the clinical course of skeletal, cardiac, and gastrointestinal muscle manifestations and trends in age at diagnosis and survival of Duchenne muscular dystrophy (DMD) patients. A retrospective cohort of 33 male patients with DMD, born between 1953 and 1983 and followed at the Mayo Clinic during their second decade of life, was studied. The mean age at DMD diagnosis was 4.6 years. Skeletal muscle weakness present in all patients at diagnosis progressed to wheelchair dependency in 32 patients (97%) by the age of 13 years (median age 10 years). Cardiac muscle failure developed in 5 patients (15%) (median age 21.5 years). Smooth muscle manifestations related to the digestive and urinary tracts occurred in 7 (21%) and 2 (6%) patients (median age 15 years), respectively. The gastrointestinal dilatations were primary in 2 patients or secondary to surgery or acute respiratory illness in 5 patients. By the end of the study period, 17 deaths had occurred (median age 17 years). Over time, there was a decrease in the time to DMD diagnosis (P = .05) but no significant change in survival (P = .44). Cardiac and smooth muscle manifestations occur late in the course of DMD. Clinical gastrointestinal symptoms related to smooth muscle function most often were secondary to surgery or a respiratory illness. In recent years, the diagnosis of DMD has been made at a younger age, but survival has not changed.

Citing Articles

The utility of muscle magnetic resonance imaging in idiopathic inflammatory myopathies: a scoping review.

Paik J, Christopher-Stine L, Boesen M, Carrino J, Eggleton S, Denis D Front Immunol. 2025; 16:1455867.

PMID: 39931069 PMC: 11808160. DOI: 10.3389/fimmu.2025.1455867.


Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model.

Hasegawa J, Nagata T, Ihara K, Tanihata J, Ebihara S, Yoshida-Tanaka K Nat Commun. 2024; 15(1):7530.

PMID: 39327422 PMC: 11427662. DOI: 10.1038/s41467-024-48204-5.


Transcriptome and Metabolome Profiling Provide New Insights into Disuse Muscle Atrophy in Chicken: The Potential Role of Fast-Twitch Muscle Fibers.

Yao Z, Guo L, Zhang L, Nie Q Int J Mol Sci. 2024; 25(6).

PMID: 38542488 PMC: 10971063. DOI: 10.3390/ijms25063516.


Evaluation of an AAV9-mini-dystrophin gene therapy candidate in a rat model of Duchenne muscular dystrophy.

Le Guiner C, Xiao X, Larcher T, Lafoux A, Huchet C, Toumaniantz G Mol Ther Methods Clin Dev. 2023; 30:30-47.

PMID: 37746247 PMC: 10512999. DOI: 10.1016/j.omtm.2023.05.017.


Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.

Bez Batti Angulski A, Hosny N, Cohen H, Martin A, Hahn D, Bauer J Front Physiol. 2023; 14:1183101.

PMID: 37435300 PMC: 10330733. DOI: 10.3389/fphys.2023.1183101.